MASTER DAPT OAC
![MASTER DAPT](/sites/g/files/qlpvch321/files/2022-09/clinical_evidence_master_dapt_logo.png)
![MASTER DAPT OAC summary document (image)](/sites/g/files/qlpvch321/files/styles/evidence_download_image_pc/public/2022-10/img-masterdapt-oac.png?itok=H3JwKeDt)
Overview
![Icon of magnigying glass (image)](/sites/g/files/qlpvch321/files/styles/large/public/2022-09/clinical_evidence_master_dapt_icon_magnifying_glass_200x200_0.png?itok=HTHomZVv)
Investigator-initiated
global randomized study
global randomized study
![Icon of globe (image)](/sites/g/files/qlpvch321/files/styles/large/public/2022-09/clinical_evidence_master_dapt_icon_globe_200x200_0.png?itok=Hlrq13LZ)
4,579 patients,
140 hospital worldwide, 30 countries
140 hospital worldwide, 30 countries
![Icon of stethoscope (image)](/sites/g/files/qlpvch321/files/styles/large/public/2022-09/clinical_evidence_master_dapt_icon_stethoscope_200x200_0.png?itok=2I1QfBYt)
All-comers trial in
HBR patients after PCI
HBR patients after PCI
![Icon of microscope (image)](/sites/g/files/qlpvch321/files/styles/large/public/2022-09/clinical_evidence_master_dapt_icon_microscope_200x200_0.png?itok=_yzFGiak)
Abbreviated vs prolonged
DAPT in patients treated with
the Ultimaster™and Ultimaster™ Tansei™ DES
DAPT in patients
treated with the
Ultimaster™ and
Ultimaster™Tansei™
DES
treated with the
Ultimaster™ and
Ultimaster™Tansei™
DES
Study Design
![Design about clinical evidence of MASTER DAPT OAC (image)](/sites/g/files/qlpvch321/files/styles/free_crop/public/2022-09/clinical_evidence_master_dapt_oac_study_design_1844x1140.png?itok=eW6Nqxjv)
Primary Endpoint
- Net adverse clinical events (NACE) defined as a composite of death from any cause, myocardial infarction, stroke or major bleeding.
- Major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of death from any cause, myocardial infarction, stroke or major bleeding.
- Major or clinically relevant non-major bleeding (MCB), defined as BARC 2, 3 or 5 bleeding.
Result
NACE
OAC indication HR 0.83, 95% CI 0.60-1.15;
p=0.26 No OAC indication HR HR 1.01, 95% CI 0.77-1.33;
p=0.91 Pinteraction=0.28
p=0.26 No OAC indication HR HR 1.01, 95% CI 0.77-1.33;
p=0.91 Pinteraction=0.28
![clinical_evidence_master_dapt_oac_nace_1844x1140](/sites/g/files/qlpvch321/files/styles/free_crop/public/2022-09/clinical_evidence_master_dapt_oac_nace_1844x1140_0.png?itok=cWMi4Hfb)
MACCE
OAC indication HR0.88, 95% CI 0.60-1.30;
p=0.53 No OAC indication HR 1.06, 95% CI 0.79-1.44;
p=0.67 Pinteraction=0.46
p=0.53 No OAC indication HR 1.06, 95% CI 0.79-1.44;
p=0.67 Pinteraction=0.46
![clinical_evidence_master_dapt_oac_macce_1844x1140](/sites/g/files/qlpvch321/files/styles/free_crop/public/2022-09/clinical_evidence_master_dapt_oac_macce_1844x1140_0.png?itok=S88y4Gn6)
Major or clinically relevant non-major bleeding
OAC indication HR 0.83, 95% CI 0.62-1.12; p=0.25
No OAC indication HR 0.55, 95% CI 0.41-0.74; p<0.001P
Pinteraction=0.06
No OAC indication HR 0.55, 95% CI 0.41-0.74; p<0.001P
Pinteraction=0.06
![clinical_evidence_master_dapt_oac_mcb_1844x1140](/sites/g/files/qlpvch321/files/styles/free_crop/public/2022-09/clinical_evidence_master_dapt_oac_mcb_1844x1140_0.png?itok=2Zy2T03z)
MASTER DAPT study is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe.